Relative bioavailability of three different solid forms of PNU-141659 as determined with the artificial stomach-duodenum model

Journal of Pharmaceutical Sciences

Volumn 99, Issue 9, 2010, Pages 3923-3930

  Carino, Stephen R ^a,b   Sperry, David C ^a,c   Hawley, Michael ^a  

^a PFIZER INC   (United States)

^b GLAXOSMITHKLINE   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Amorphous; Dissolution; Hydrate; In vitro models; Polymorphism; Preformulation

Indexed keywords

ANTIINFECTIVE AGENT; PNU 141659; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL ORGAN; CRYSTAL; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DUODENUM FLUID; EXPERIMENTAL MODEL; SOLID; STOMACH JUICE;

EID: 77956355460     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22236     Document Type: Article

References (18)

1. US Pharmacopeia & National Formulary. 1995. US Pharmacopeial Convention. Washington, DC.
2. Minekus M, Marteau P, Havenaar R, Huis In't Veld JHJ. 1995. A multicompartmental dynamic computer-controlled model simulating the stomach and small-intestine. ATLA: Altern Lab Anim 23:197-209.
3. Minekus M, Smeets-Peeters M, Bernalier A, Marol-Bonnin A, Havenaar R, Marteau P, Alric M, Fonty G, Huis In't Veld JHJ. 1999. Computer-controlled system to simulate conditions of the large intestine with peristaltic mixing, water absorption and absorption of fermentation products. Appl Microbiol Biotechnol 53:108-114.
4. Larsson M, Minekus M, Havenaar R. 1997. Estimation of the bioavailability of iron and phosphorus in cereals using a dynamic in vitro gastrointestinal model. J Sci Food Agric 74:99-106. (Pubitemid 27236211)
5. Marteau P, Minekus M, Havenaar R, Huis In't, Veld JHJ. 1997. Survival of lactic acid bacteria in a dynamic model of the stomach and small intestine: Validation and the effects of bile. J Dairy Sci 80:1031-1037.
6. Vatier J, Lionnet F, Vitre MT, Mignon M. 1988. A model of an 'artificial stomach' for assessing the characteristics of an antacid. Aliment Pharmacol Ther 2:461-470.
7. Vatier J, Ramdani A, Vitre MT, Mignon M. 1994. Antacid activity of calcium carbonate and hydrotalcite tablets: Comparison between in vitro evaluation using the "artificial stomachduodenum" model and in vivo pH-metry in healthy volunteers. Arzneimittelforschung 44:514-518.
8. Papin-Castela N, Grandpierre I, Celice-Pingaud C, Chenevier P, Vatier J, Farinotti R. 1999. Drug interactions involving diosmectite studied with an artificial stomach-duodenum model: Application to AIDS therapy. J Pharm Clin 18:131-137.
9. Kobayashi M, Sada N, Sugawara M, Iseki K, Miyazaki K. 2001. Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract. Int J Pharm 221:87-94.
10. He X, Sugawara M, Kobayashi M, Takekuma Y, Miyazaki K. 2003. An in vitro system for prediction of oral absorption of relatively water-soluble drugs and ester prodrugs. Int J Pharm 263:35-44.
11. Carino SR, Sperry DC, Hawley M. 2006. Relative bioavailability estimation of carbamazepine crystal forms using an artifi- cial stomach-duodenum model. J Pharm Sci 95:116-125.
12. Stahl PH, Nakana M. 2002. Pharmaceutical aspects of the drug salt form. In: Stahl PH, Wermuth CG, editors. Handbook of pharmaceutical salts: Properties, selection and use. Switzerland: Verlag Helvetica Chimica Acta, Zurich. pp 83-116.
13. Smeets-Peeters M, Watson T, Minekus M, Havenaar R. 1998. A review of the physiology of the canine digestive tract related to the development of in vitro systems. Nutr Res Rev 11:45-69. (Pubitemid 128532835)
14. Dressman JB. 1986. Comparison of canine and human gastrointestinal physiology. Pharm Res 3:123-131.
15. Dozois RR, Kelly KA, Code CF. 1971. Effect of distal antrectomy on gastric emptying of liquids and solids. Gastroenterology 61:675-681.
16. Peng GW, Stryd RP, Amidon GE, Hageman MJ, Van de Giessen TL, Brewer JE, Gao P, Price JE, Secreast PJ, Jones BW, Morozowich WM, Rousch KE, Lu Q, Wald RJ, Debrincat GA, Dalga RJ, Huang T, Douglas SL, Stodola JD. 2000. Pfizer unpublished results.
17. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-12.
18. Kawakami K. 2009. Current status of amorphous formulation and other special dosage forms as formulations for early clinical phases. J Pharm Sci 98:2875-2885.